Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: A multivariate analysis in 343 patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 2, 1997, Pages 149-155

  Kuwana, Kenji ^a   Ichida, Takafumi ^a   Kamimura, Tomoteru ^a,b   Ohkoshi, Showgo ^a   Ogata, Norio ^a   Harada, Takeshi ^a   Endoh, Kazuo ^c   Asakura, Hitoshi ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b Saiseikai Niigata Dai Ni Hospital   (Japan)

^c NONE

Author keywords

Chronic liver disease; Hepatitis C virus; Hepatocellular carcinoma; Incidence rate; Interferon therapy; Multivariate analysis; Person year method

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; VIRUS HEPATITIS;

EID: 0031026902     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00398.x     Document Type: Article

References (35)

1. Health and Welfare Statistics Association. Vital statistics. J. Health Welfare Stat. 1993; 40: 42-72.
2. Liver Cancer Study Group of Japan. Primary liver cancer in Japan (clinicopathologic features and results of surgical treatment). Ann. Surg. 1990; 211: 277-87.
3. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan. Report 11. Acta Hepatol. Jpn. 1995; 36: 208-18 (in Japanese).
4. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Gastroenterology 1988; 94: 453-6.
5. Livraghi T, Bolondi L, Lazzaroni S et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. Cancer 1992; 69: 925-9.
6. Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J Med. 1993; 328: 1797-801.
7. Ohnishi K, Iida D, Iwama S et al. The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma. Cancer 1982; 49: 672-7.
8. Takada N, Takase S, Enomoto N, Takada A, Date T. Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol. 1992; 14: 35-40.
9. Silini E, Bono F, Cividini A et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995; 21: 285-90.
10. Nousbaum JB, Pol S, Nalpas B et al. Hepatitis C virus type 1b (II) infection in France and Italy. Ann. Intern. Med. 1995; 122: 161-8.
11. Mita K, Hayashi N, Kanazawa Y et al. Hepatitis C virus genotype and RNA titer in the progression of type C chronic liver disease. J. Hepatol. 1994; 21: 468-73.
12. Yamada M, Kakumu S, Yoshioka K et al. Hepatitis C virus genotypes are not responsible for development of serious liver disease. Dig. Dis. Sci. 1994; 39: 234-9.
13. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 1995; 21: 650-5.
14. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J. Gen. Virol. 1992; 72: 673-9.
15. Urdea MS, Horn T, Fultz TJ et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis virus. Nucleic Acids Res. Symp. Series 1991; 24: 197-200.
16. Sherman KE, O'Brien J, Gutierrez AG et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin. Microbiol. 1993; 31: 2679-82.
17. Gilliland G, Perrin S, Blanchard K, Bunn HF. Analysis of cytokine mRNA and DNA: Detection and quantitation by competitive polymerase chain reaction. Proc. Natl Acad. Sci. USA 1990; 87: 2725-9.
18. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: Increase of the virus in advanced liver disease. Hepatology 1993; 18: 16-20.
19. Mausner JD, Kramer S. Epidemiology: An Introductory Text, 2nd edn. Philadelphia: WB Saunders Company, 1984.
20. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
21. Alberti A, Morsica G, Chemello L et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697-8.
22. Brillanti S, Foli M, Gaiani S, Masci C, Miglioli M, Barbara B. Persistent hepatitis C viraemia without liver disease. Lancet 1993; 341: 464-7.
23. Tong MJ, El-Farra NS, Reikes AR, Ruth L. Clinical outcomes after transfusion-associated hepatitis C. N Engl. J. Med. 1995; 332: 1463-6.
24. Lieber CS, Seitz HK, Garro AJ, Worner TM. Alcohol-related diseases and carcinogenesis. Cancer Res. 1979; 39: 2863-6.
25. Tsutsumi M, Matsuda Y, Takada A. Role of ethanol-inducible cytochrome P-450 2E1 in the development of hepatocellular carcinoma by the chemical carcinogen, N-Nitrosodimethylamine. Hepatology 1993; 18: 1483-9.
26. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
27. Mita E, Hayashi N, Kanazawa Y et al. Hepatitis C virus genotype and RNA titer in the progression of type C chronic liver disease. J. Hepatol. 1994; 21: 468-73.
28. Yotsuyanagi H, Koike K, Yasuda K et al. Hepatitis C virus genotypes and development of hepatocellular carcinoma. Cancer 1995; 76: 1352-5.
29. Hagiwara H, Hayashi N, Mita E et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993; 17: 545-50.
30. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohoto M, Omata M. Quantitation of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: Increase of the virus in advanced liver disease. Hepatology 1993; 18: 16-20.
31. Davis GL, Galart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter, randomized, controlled trial. N. Engl. J. Med. 1989; 321: 1501-6.
32. Colleoni M, Buzzoni R, Bajetta E et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 1993; 72: 3196-201.
33. Sachs E, Di Bisceglie AM, Dusheiko GM et al. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: A pilot study. Br. J. Cancer 1985; 52: 105-9.
34. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
35. Mazzella G, Accogli E, Sottili S et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J. Hepatol. 1996; 24: 141-7.